Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2017 (2017), Article ID 6178358, 11 pages
https://doi.org/10.1155/2017/6178358
Research Article

Yinchen Linggui Zhugan Decoction Ameliorates Nonalcoholic Fatty Liver Disease in Rats by Regulating the Nrf2/ARE Signaling Pathway

1Beijing University of Chinese Medicine, No. 11, North Third Ring East Road, Beijing 100029, China
2Gastroenterology Department, Dongfang Hospital, Beijing University of Chinese Medicine, No. 6, 1st Section, Fangxingyuan, Fangzhuang, Beijing 100078, China

Correspondence should be addressed to Hai-xiao Han

Received 17 May 2017; Revised 11 July 2017; Accepted 30 July 2017; Published 28 August 2017

Academic Editor: Jing-Hua Wang

Copyright © 2017 Yi Guo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. A. Sass, P. Chang, and K. B. Chopra, “Nonalcoholic fatty liver disease: a clinical review,” Digestive Diseases and Sciences, vol. 50, no. 1, pp. 171–180, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Charlton, “Nonalcoholic fatty liver disease: a review of current understanding and future impact,” Clinical Gastroenterology and Hepatology, vol. 2, no. 12, pp. 1048–1058, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Vuppalanchi and N. Chalasani, “Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management,” Hepatology, vol. 49, no. 1, pp. 306–317, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. J.-H. Ryoo, Y. J. Suh, H. C. Shin, Y. K. Cho, J.-M. Choi, and S. K. Park, “Clinical association between non-alcoholic fatty liver disease and the development of hypertension,” Journal of Gastroenterology and Hepatology (Australia), vol. 29, no. 11, pp. 1926–1931, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. J.-H. Ryoo, W. T. Ham, J.-M. Choi et al., “Clinical significance of non-alcoholic fatty liver disease as a risk factor for prehypertension,” Journal of Korean Medical Science, vol. 29, no. 7, pp. 973–979, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Katsiki, D. P. Mikhailidis, and C. S. Mantzoros, “Non-alcoholic fatty liver disease and dyslipidemia: An update,” Metabolism: Clinical and Experimental, vol. 65, no. 8, pp. 1109–1123, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. J. K. Dowman, J. W. Tomlinson, and P. N. Newsome, “Pathogenesis of non-alcoholic fatty liver disease,” QJM, vol. 103, no. 2, pp. 71–83, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Enjoji, K. Yasutake, M. Kohjima, and M. Nakamuta, “Nutrition and nonalcoholic fatty liver disease: the significance of cholesterol,” International Journal of Hepatology, vol. 2012, 6 pages, 2012. View at Publisher · View at Google Scholar
  9. G. F. Watts, “Nutrition and metabolism: nutritional therapy for disordered triglyceride metabolism and nonalcoholic fatty liver disease,” Current Opinion in Lipidology, vol. 21, no. 6, pp. 545–547, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. D. B. Andrews and J. E. Lavine, “Medical therapy for nonalcoholic fatty liver disease in children and adolescents,” Expert Review of Gastroenterology and Hepatology, vol. 6, no. 1, pp. 1–3, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Eckard, R. Cole, J. Lockwood et al., “Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial,” Therapeutic Advances in Gastroenterology, vol. 6, no. 4, pp. 249–259, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Tock, A. R. Dâmaso, A. de Piano et al., “Long-term effects of metformin and lifestyle modification on nonalcoholic fatty liver disease obese adolescents,” Journal of Obesity, vol. 2010, Article ID 831901, 6 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. R. C. Smith, “Metformin as a treatment for antipsychotic drug side effects: special focus on women with schizophrenia,” The American Journal of Psychiatry, vol. 169, no. 8, pp. 774–776, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. Z. Du H, L. Luo, J. Hou Y et al., “study on HPLC fingerprints of Yinchenhao decoction and attributive analysis of common peaks,” Journal of Nan Jing University of Tcm, vol. 31, no. 4, pp. 380–384, 2015. View at Google Scholar
  15. Z. Song H, D. Feng, J. Xu B et al., “Study on the compatibility and therapeutic basis of composite herbal medicines of Lingguizhugan Decoction,” Chinese Traditional Patent Medicine, vol. 25, no. 2, pp. 132–137, 2003. View at Google Scholar
  16. M. Tang-you, G. Kang-li, Z. Wei-han et al., “Experimental study of “Wenyun Qingli” method on DAG-PKCε signal pathway in liver tissue of NASH rats,” Global Traditional Chinese Medicine, vol. 9, no. 8, pp. 908–913, 2016. View at Google Scholar
  17. Z. Dan, S. Ting-ting, C. Lan-yu et al., “Treatment of nonalcoholic fatty liver disease in Jingui Yaolue,” Journal of Changchun University of Chinese Medicine, vol. 32, no. 2, pp. 423–425, 2016. View at Google Scholar
  18. M. Bahabadi, A. Mohammadalipour, J. Karimi et al., “Hepatoprotective effect of parthenolide in rat model of nonalcoholic fatty liver disease,” Immunopharmacology & Immunotoxicology, vol. 39, no. 4, pp. 233–242, 2017. View at Google Scholar
  19. D. Lee H, D. Han H, K. Nam T et al., “Ezetimibe, an NPC1L1 inhibitor, is a potent Nrf2 activator that protects mice from diet-induced nonalcoholic steatohepatitis,” Free Radical Biology & Medicine, vol. 10, no. 99, pp. 520–532, 2016. View at Google Scholar
  20. J. Du, M. Zhang, J. Lu et al., “Osteocalcin improves nonalcoholic fatty liver disease in mice through activation of Nrf2 and inhibition of JNK,” Endocrine, vol. 53, no. 3, pp. 701–709, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Cai, M. Yuan, D. F. Frantz et al., “Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB,” Nature Medicine, vol. 11, no. 2, pp. 183–190, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Tanaka, L. M. Aleksunes, R. L. Yeager et al., “NF-E2-related factor 2 inhibits lipid accumulation and oxidative stress in mice fed a high-fat diet,” Journal of Pharmacology and Experimental Therapeutics, vol. 325, no. 2, pp. 655–664, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Chowdhry, M. H. Nazmy, P. J. Meakin et al., “Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis,” Free Radical Biology and Medicine, vol. 48, no. 2, pp. 357–371, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Sugimoto, K. Okada, J. Shoda et al., “Deletion of nuclear factor-E2-related factor-2 leads to rapid onset and progression of nutritional steatohepatitis in mice,” American Journal of Physiology: Gastrointestinal and Liver Physiology, vol. 298, no. 2, pp. G283–G294, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. Y.-K. J. Zhang, R. L. Yeager, Y. Tanaka, and C. D. Klaassen, “Enhanced expression of Nrf2 in mice attenuates the fatty liver produced by a methionine- and choline-deficient diet,” Toxicology and Applied Pharmacology, vol. 245, no. 3, pp. 326–334, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Itoh, N. Wakabayashi, Y. Katoh et al., “Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain,” Genes & Development, vol. 13, no. 1, pp. 76–86, 1999. View at Google Scholar
  27. A. Kobayashi, M. Kang, H. Okawa et al., “Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2,” Molecular and Cellular Biology, vol. 24, no. 16, pp. 7130–7139, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Barbuio, M. Milanski, M. B. Bertolo, M. J. Saad, and L. A. Velloso, “Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet,” Journal of Endocrinology, vol. 194, no. 3, pp. 539–550, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. V. T. Samuel, Z.-X. Liu, X. Qu et al., “Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease,” The Journal of Biological Chemistry, vol. 279, no. 31, pp. 32345–32353, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. K.-X. Gan, C. Wang, J.-H. Chen, C.-J. Zhu, and G.-Y. Song, “Mitofusin-2 ameliorates high-fat diet-induced insulin resistance in liver of rats,” World Journal of Gastroenterology, vol. 19, no. 10, pp. 1572–1581, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. J. C. Fraulob, R. Ogg-Diamantino, C. Fernandes-Santos, M. B. Aguila, and C. A. Mandarim-de-Lacerda, “A mouse model of metabolic syndrome: insulin resistance, fatty liver and Non-Alcoholic Fatty Pancreas Disease (NAFPD) in C57BL/6 mice fed a high fat diet,” Journal of Clinical Biochemistry and Nutrition, vol. 46, no. 3, pp. 212–223, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. Zhang, P. Talalay, C. G. Cho, and G. H. Posner, “A major inducer of anti-carcinogenic protective enzymes from broccoli: isolation and elucidation of structure,” in Proceedings of the National Academy of Sciences of the United States of America USA, vol. 89, pp. 2399–2403, 1992.
  33. E. Smirnova, L. Griparic, D.-L. Shurland, and A. M. van der Bliek, “Dynamin-related protein Drp1 is required for mitochondrial division in mammalian cells,” Molecular Biology of the Cell, vol. 12, no. 8, pp. 2245–2256, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. Zhang and L. Tang, “Discovery and development of sulforaphane as a cancer chemopreventive phytochemical,” Acta Pharmacologica Sinica, vol. 28, no. 9, pp. 1343–1354, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Fan, D. Liu, C. He, X. Li, and F. He, “Inhibiting adhesion events by Panax notoginseng saponins and Ginsenoside Rb1 protecting arteries via activation of Nrf2 and suppression of p38 – VCAM-1 signal pathway,” Journal of Ethnopharmacology, vol. 192, pp. 423–430, 2016. View at Publisher · View at Google Scholar · View at Scopus
  36. X. Liu, C. Xavier, J. Jann, and H. Wu, “Salvianolic acid B (Sal B) protects retinal pigment epithelial cells from oxidative stress-induced cell death by activating glutaredoxin 1 (Grx1),” International Journal of Molecular Sciences, vol. 17, no. 11, article no. 1835, 2016. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Li, F. Song, L.-R. Duan et al., “Paeonol and danshensu combination attenuates apoptosis in myocardial infarcted rats by inhibiting oxidative stress: Roles of Nrf2/HO-1 and PI3K/Akt pathway,” Scientific Reports, vol. 6, Article ID 23693, 2016. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Li, J. Yu, H. Ma et al., “Intranasal Pretreatment with Z-Ligustilide, the Main Volatile Component of Rhizoma Chuanxiong, Confers Prophylaxis against Cerebral Ischemia via Nrf2 and HSP70 Signaling Pathways,” Journal of Agricultural and Food Chemistry, vol. 65, no. 8, pp. 1533–1542, 2017. View at Publisher · View at Google Scholar · View at Scopus
  39. C.-W. Pan, G.-Y. Zhou, W.-L. Chen et al., “Protective effect of forsythiaside A on lipopolysaccharide/d-galactosamine-induced liver injury,” International Immunopharmacology, vol. 26, no. 1, pp. 80–85, 2015. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Bao, R. DIng, L. Zou et al., “Forsythiae Fructus Inhibits B16 Melanoma Growth Involving MAPKs/Nrf2/HO-1 Mediated Anti-Oxidation and Anti-Inflammation,” American Journal of Chinese Medicine, vol. 44, no. 5, pp. 1043–1061, 2016. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Ji, Z. Li, W. Song et al., “Bioactive Constituents of Glycyrrhiza uralensis (Licorice): Discovery of the Effective Components of a Traditional Herbal Medicine,” Journal of Natural Products, vol. 79, no. 2, pp. 281–292, 2016. View at Publisher · View at Google Scholar · View at Scopus
  42. Z. Chen, X. Ma, Y. Zhao et al., “Yinchenhao decoction in the treatment of cholestasis: A systematic review and meta-analysis,” Journal of Ethnopharmacology, vol. 168, pp. 208–216, 2015. View at Publisher · View at Google Scholar · View at Scopus